Congress does not pass 'most favored nation' drug pricing law in 2026

Pharma leaders oppose the policy, citing concerns about care rationing and free market principles. Republican congressional opposition makes passage unlikely, but industry will remain vigilant.

Implied probability (Yes)

85%